This study has demonstrated that biomarkers of systemic inflammation and malnutrition independently predict survival in patients with NSCLC expressing PD-L1 ≥50% treated with first-line pembrolizumab monotherapy. This evidence concerns the gene CD274 and nutritional deficiency disease.